//
sign in
Profile
by @danabra.mov
Profile
by @dansshadow.bsky.social
Profile
by @jimpick.com
AviHandle
by @danabra.mov
AviHandle
by @dansshadow.bsky.social
AviHandle
by @katherine.computer
EventsList
by @katherine.computer
ProfileHeader
by @dansshadow.bsky.social
ProfileHeader
by @danabra.mov
ProfileMedia
by @danabra.mov
ProfilePlays
by @danabra.mov
ProfilePosts
by @danabra.mov
ProfilePosts
by @dansshadow.bsky.social
ProfileReplies
by @danabra.mov
Record
by @atsui.org
Skircle
by @danabra.mov
StreamPlacePlaylist
by @katherine.computer
+ new component
Profile
Loading...
D2R | DNA to RNA is a research initiative at McGill University taking an inclusive Canadian approach to developing genomic-based #RNA therapies for rare diseases, infectious diseases and cancer. www.mcgill.ca/dna-to-rna/ www.youtube.com/@D2RMcGill
D2R | DNA to RNA









Loading...
🧬#D2RProjectSpotlight: Targeting miRNAs in Embryonal Brain Tumors (@mcgillu Prof. Jacek Majewski) This project will study the molecular effects of this genome rearrangement and explore the use of microRNA inhibitors – sponges – to counteract the oncogenic changes buff.ly/309J3d2
Now in @natchem.nature.com: Antibodies dominate drug development—but they’re big, costly, and can trigger immune reactions. #McGill professors Hanadi Sleiman & Maureen McKeague introduce Alenomers: barcoded aptamers with antibody‑level chemical diversity, screenable at massive scale buff.ly/BKKN4zS
🧬#D2RProjectSpotlight: Switchable self-amplifying RNA: Safe, Selective, and Programmable Therapeutic Expression led by Prof. Maureen McKeague with collaborator Prof. Anna Blakney 🔗Learn more here: buff.ly/hlfhhvb
And that's a wrap on Day 1 of the #D2RSymposium2026 🎉 All of today’s sessions highlighted that the research, both within the D2R community and beyond, is full of exciting developments. Stay tuned for even more on Day 2 tomorrow!
#D2RSymposium2026 is underway! Sharing a few highlights from the action 📸 Tune into our LinkedIn for all the updates! 🧬 #RNATherapeutics
D2R awards nearly $6M in funding to support 4 Translational Impact research projects focused on advancing RNA-based therapies for cancer and rare genetic diseases. 🔗 Learn more about these projects and the funded professors here: buff.ly/TPzPPdH
🌟 The #D2RSymposium2026 is officially underway! Today and tomorrow we will be posting highlights of the event on our LinkedIn including inspiring talks, innovative research, trainee presentations, and more in #RNAtherapeutics.💡Big MERCI to all our sponsors! buff.ly/YzOWyGL
🔊 #D2RProjectSpotlight: D2R - Health Data Science (D2R-HeDS) platform 💡 Scientific Director: Guillaume Bourque (@McGillu) 🔗 Learn more: buff.ly/qDphDDy #RNA #RNATherapy #RNAResearch
🌟D2R is seeking a strategic and collaborative leader to join our team as Associate Director, Indigenous Health Research for D2R. This role supports Indigenous-led health research, fosters strong partnerships with Indigenous communities & organizations and more! Learn more: buff.ly/zxV3Uxx
#D2RProjectSpotlight: End to end sequencing platform for RNA therapeutics quality control (EESPRNATQC) Scientific Director: Ioannis Ragoussis (@mcgillu)🔗 Learn more here: buff.ly/zhzGYc7
1mo
1mo
1mo
1mo
1mo
1mo
1mo
3mo
2mo
3mo
www.mcgill.ca
D2R | DNA to RNA
D2R | DNA to RNA
D2R | DNA to RNA
D2R | DNA to RNA
D2R | DNA to RNA
D2R | DNA to RNA
D2R | DNA to RNA
D2R | DNA to RNA
D2R | DNA to RNA
D2R | DNA to RNA